Provided by Tiger Trade Technology Pte. Ltd.

Agree

74.97
+0.56000.75%
Post-market: 74.970.00000.00%16:10 EDT
Volume:1.44M
Turnover:108.29M
Market Cap:9.00B
PE:42.36
High:76.07
Open:75.14
Low:74.55
Close:74.41
52wk High:82.08
52wk Low:68.98
Shares:120.03M
Float Shares:108.37M
Volume Ratio:1.14
T/O Rate:1.33%
Dividend:3.08
Dividend Rate:4.11%
EPS(TTM):1.77
EPS(LYR):1.77
ROE:3.48%
ROA:2.37%
PB:1.48
PE(LYR):42.36

Loading ...

Press Release: Agree Realty Declares Monthly Common and Preferred Dividends

Dow Jones
·
Jan 14

Biocytogen Pharma Expands ADC Collaboration with Acepodia; Shares Rise 9%

MT Newswires Live
·
Jan 13

Hong Kong Stock Movement | HENLIUS (02696) Surges Over 8% Again, Broad-Spectrum Anti-Tumor PD-L1 ADC HLX43 Phase II Data for End-Line Esophageal Squamous Cell Carcinoma First Released

Stock News
·
Jan 13

Top Insider Makes Bold Move With Major Agree Realty Stock Purchase

TIPRANKS
·
Jan 13

RPMGlobal Holdings Says Caterpillar, FIRB Agree to Extend Deadline for Approval for Proposed Acquisition

MT Newswires Live
·
Jan 13

Executive Chairman Richard Agree Acquires Common Shares of Agree Realty Corporation

Reuters
·
Jan 13

Agree Realty Corp : Bmo Cuts Target Price to $80 From $85

THOMSON REUTERS
·
Jan 12

Zymeworks Sets 2026 Strategy on Zanidatamab Momentum, ADC Pipeline and Cash-Fueled Growth

TIPRANKS
·
Jan 12

Zymeworks Outlines Strategic Priorities and Outlook for 2026

GlobeNewswire
·
Jan 12

Day One Announces Preliminary 2025 OJEMDA™ Net Product Revenue And Provides 2026 Net Product Revenue Guidance

GlobeNewswire
·
Jan 12

Why Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) Is Up 18.9% After Breakthrough ADC Milestones And Global Tie-Up

Simply Wall St.
·
Jan 10

Beyond the Title: The Significance Behind the Recognition

Deep News
·
Jan 09

ADC Therapeutics Announces Preliminary 2025 Financial Results and Outlook

TIPRANKS
·
Jan 09

ADC Therapeutics sees FY25 net product revenue $73M

TIPRANKS
·
Jan 09

ADC Therapeutics sees Q4 net product revenue $22M

TIPRANKS
·
Jan 09

ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004

GlobeNewswire
·
Jan 08

UBS Keeps Their Buy Rating on Agree Realty (ADC)

TIPRANKS
·
Jan 08

Chengdu Hosts Nearly 70% of Sichuan's Corporate Headquarters: The Story Behind the Numbers

Deep News
·
Jan 08

HENLIUS (02696) Surges Over 5% Intraday as Company Unveils First Phase II Clinical Data for PD-L1 ADC in Esophageal Squamous Cell Carcinoma

Stock News
·
Jan 08

Top News Today/Canada: Air Transat, Pilots Agree to Deal

Dow Jones
·
Jan 07